A human papillomavirus type 11 (HPV-11) early gene promoter, PE1ˆE4, in the E7 open reading frame and involved in the transcription of E1ˆE4 and E1ˆE4, L1 mRNAs was characterized by chloramphenicol acetyl transferase (CAT) assay, gel-shift assay, in vitro transcription, and primer extension. By CAT assay with CAT-expression plasmids containing various portions of the HPV-11 genome from nucleotide position (nt) 235 to nt 743, we identified a 112-basepair (bp) sequence (nt 632-743) that had high promoter activity and a 188-bp upstream sequence from nt 395 to nt 572 that strongly suppressed activity. The 112-bp sequence contained a 7-bp repeat (7-bp Rep) with high homology to the Sp1-binding motif (BM) in the E6 promoter of HPV-11 but lacked an identifiable TATA-box. A cellular protein other than Sp1 bound to the 7-bp Rep. Removal of a 21-bp segment (nt 632-652) containing the 7-bp Rep significantly reduced activity. By in vitro transcription assay and primer extension, one of the transcription start sites was mapped to near nt 719. These results suggested that a cellular protein that binds to the 7-bp Rep may act as an activator for PE1ˆE4. ᭧
INTRODUCTION
amplification of cDNAs, a bicistronic mRNA, E1ˆE4, L1, which encodes E1ˆE4 and L1 proteins, was detected (RoHuman papillavirus virus type 11 (HPV-11) is a mucotenberg et al., 1989; Tomita and Simizu, 1993) . Thus, transal type HPV that induces benign tumors such as condyscription of the mRNA encoding the E1ˆE4, E1, E1-M, E2, loma acuminata and laryngeal papilloma. In these tumors E2-C, and L1 protein appears to be driven by the same and in HPV-11-infected human tissue implanted into promoter. In the work described in this paper, we characterathymic mice, E1ˆE4 mRNA, which encodes the E1ˆE4 ized the promoter PE1ˆE4 in the E7 ORF of HPV-11. fusion protein, is the most abundant viral mRNA (Nasseri et al., 1987; Chow et al., 1987; Stoler et al., 1990) . By R-MATERIALS AND METHODS loop analysis (Chow et al., 1987) , the 5-ends of the CAT expression plasmids E1ˆE4 mRNAs and of other mRNAs encoding E1-M, E2-C, and E2 proteins have been mapped to near nucleotide To construct CAT expression assay plasmids, we used (nt) 700 in the E7 open reading frame (ORF). Smotkin et pSV2CAT (Gorman et al., 1982) , pTV119N (Takara Shuzo al. (1989) used S1 nuclease to map the 5-ends of the Co. Ltd., Japan), pCAT-Enhancer (Promega Co. Ltd., Mad-E1ˆE4 mRNAs to a heterogeneous cluster of sites around ison, WI). Promoter activity of the BamHI (nt 7072) to nt 674-714, and Nasseri et al. (1987) mapped the 5-ApaLI (nt 743) sequence within the HPV 11 genome was ends to nt 716 by cDNA cloning. Therefore, a promoter tested using constructs derived from pSV2CAT, pCAThas been presumed to exist in the E7 ORF (Chow et al., Enhancer, and pTV119N. pCAT/19 was constructed by 1987; Smotkin et al., 1989) .
blunt-end ligating into the EcoRI site of pTV119N a The promoter of HPV-11 most studied is the E6 propSV2CAT HindIII-BamHI fragment containing the bactemoter, which drives transcription of the E6-specific rial chloramphenicol acetyl transferase (CAT) gene and mRNA. However, other promoters have yet to be studied the SV40 poly(A) signal, but lacking the SV40 enhancer. in detail. A promoter in the E7 ORF would be expected Next, the BamHI (nt 7072) to ApaLI (nt 743) sequence to be highly active during HPV replication in tumors in was inserted into the XbaI site of pCAT-Enhancer, after that expression of E1ˆE4 mRNA occurs very early during addition of XbaI linker and obtained pBA/CAT-enhancer. cellular differentiation and increases after the onset of Then, four CAT expression assay plasmids were conviral DNA replication. Eventually, E1ˆE4 mRNA accumustructed replacing a part of pTV119 and CAT gene selates to more than 98% of virus mRNAs in the epithelium quences (from the HindIII site in pTV119 to the EcoRI (Chow et al., 1987) . By polymerase chain reaction (PCR) site in pSV2CAT) with various-lengths of the E7 ORF-CAT gene fusion sequence from NdeI (nt 235 in E7 ORF) to the XbaI site (nt 2266 in pCAT-Enhancer) in pBA/CAT-CAT, pDPA/CAT, and pPA/CAT, contained fragments of extract was prepared according to the methods described by Gigman et al. (1983) , with minor modifications. the HPV 11 E7 ORF beginning at NdeI (nt 235), NdeI (nt 351), DraI (nt 392), or PstI (nt 572), respectively, and endThe reaction mixture (20 ml) contained 1 ml of HeLa-cell nuclear extract, 2 ml of 51 binding buffer (55 mM HEPES, ing at ApaLI (nt 743). pNNDPA/CAT was then used to construct a fifth plasmid, pNNDPA/CAT, by restriction pH 7.9, 250 mM KCl, 40 mM MgCl 2 , 55% glycerol, 0.5 mM EDTA, and 5 mM dithiothreitol (DTT)), 1 ml of poly(dIenzyme digestion and removal of the PstI-ApaI sequence, blunting, and ligation. The sequences of the E7 dC), 1 ml (20 fmmol) of 32 P-labeled probe and 2 to 5 ml of competitor. The binding reaction was carried out on ORF-CAT junction in the CAT expression assay plasmids (from nt 739 of HPV11 to nt 2271 in pCAT-Enhancer) were ice for 10 min, and then the products were analyzed by electrophoresis in 5% polyacrylamide in 0.51 Tris-GTGCACTCTAGA.
Several plasmids were constructed for determining the borate-EDTA buffer (45 mM Tris-borate, pH 8.0, 2 mM EDTA). effects on promoter activity of the 5-region of the HPV-11 noncoding region (NCR). The NdeI-ApaLI (nt 235-743) sequence of pNNDPA/CAT was replaced with the In vitro transcription and primer extension BamHI-AccII NCR sequence of HPV-11 (nt 7072 to nt A 439-bp DNA fragment, consisting 177 bp of HPV-11 7513) to construct pBA/CAT. Then, pBA/NDPA/CAT and DNA and 262 bp of the CAT gene, was used for in vitro pBA/PA/CAT were obtained by inserting the BamHI-Actranscription with a HeLa cell extract transcription syscII sequence into the NdeI (nt 351) and PstI (nt 572) sites tem (Promega Co. Ltd.). The 25-ml reaction mixture conof pNDPA/CAT and pPA/CAT, respectively. tained 8 units of HeLa nuclear extract, 3 mM MgCl 2 , 50 Plasmids for mapping of a minimum promoter seto 100 ng of the DNA fragment, and 0.4 mM of each quence were obtained by removing portions of the HPVdNTP. To radioactively label the RNA product, the con-11 E7 promoter sequence from pPA/CAT and pBA/PA/ centration of dGTP was decreased to 0.016 mM and 5 CAT. Portions of the promoter and part of the CAT gene mCi of [ 32 P]GTP (3000 Ci/mmol) was included. The reacin each of these plasmids were amplified by PCR using tion was carried out at 30Њ for 60 min and then the 32 Pvarious primer sets with a restriction site at the 5-end.
labeled product was analyzed on a 6% polyacrylamide Then, the promoter and CAT gene sequence in pPA/CAT sequencing gel. Restriction enzyme (HapII)-digested and and pBA/PA/CAT were replaced with these PCR products 32 P-labeled pUC19 and pTV119N DNAs (Takara Shuzo, to yield p623A/CAT, p632A/CAT, p653A/CAT, pBA/632A/ Co. Ltd.) were used as size markers. The unlabeled tran-CAT, and pBA/653A/CAT. scription product was prepared and used as a template for primer extension. The 25-ml reaction mixture con-CAT assay tained 30 mM Tris-HCl, pH 8.3, 15 mM MgCl 2 , 8 mM HeLa cells were grown in Eagle's MEM with 10% fetal DTT, 4 mM of each dNTP, 10 ml of the template RNA, 1 calf serum. Fifteen micrograms of each plasmid was ml of 32 P-labeled HS21 primer, which has a sequence mixed with 6 1 10 6 cells in glucose buffer (20 mM HEPES, corresponding to nt 2341-2359 of plasmid pCAT-En-N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, pH hancer, 0.22 mg of actinomycin D, and 5 units of reverse 7.2, 137 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 , 6 mM transcriptase. The reaction was carried out at 37Њ for 60 glucose). Cells were transfected with each plasmid in a min, stopped by addition of 12 ml of sequencing stop GTE-10 electroporation apparatus (Shimadzu Co. Ltd., buffer, and heated at 90Њ for 3 min. The product was Japan) and cultured in Eagle's MEM with 10% fetal calf analyzed in a 6% sequencing gel in which the sequencing serum. Two days later, CAT assays were carried out by products of an M13mp18-ssDNA/M13-47 primer reaction methods described elsewhere (Shirasawa et al., 1994) .
as were included as a size marker. Radioactivities of the acetylated products were calculated using the BAS-2000 Bio-imaging analyzer (Shira-RESULTS sawa et al., 1994) . Assays were done at least three times
Promoter activity of HPV-11 nt 235 to nt 743 and mean values were calculated.
To determine the sequence of PE1ˆE4 required proGel-shift assay moter activity, various portions of HPV-11 DNA from the NdeI site at nt 235 to the ApaLI site at nt 743 (Fig. 1A ) Double-stranded (ds)-oligonucleotides (5-GATGAG-GTGGACAAGGTGGA) that match the Sp1 binding motif were cloned into the HindIII site of pCAT/19 (Fig. 1B) , and CAT assays were carried out using HeLa cells. As (BM)-like sequence in the E7 ORF (7-basepair (bp) repeat, 7-bp Rep) were labeled with [g- reaction, the negative control, suggested that nonspecific shown in Fig. 2B-2 , addition of the BamHI-AccII sequence decreased nonspecific transcription of pCAT/19 transcription initiation may occur in pCAT/19. CAT activities of the other plasmids, containing NNDP, NDP, and from 17 to 7.8 relative to the activity of the pPA/CAT(100). This result indicated a partial elimination by the BamHI-DP sequences, were lower than that of pCAT/19. This suggested that the NdeI-PstI (nt 235-572) sequence or AccII sequence of the nonspecific transcription initiation from the plasmid sequence. However, in pBA/PA/CAT, even the DraI-PstI (nt 392-572) had a strong suppressive effect on PE1ˆE4.
high CAT activity was still observed, demonstrating again the presence of a promoter in the PstI-ApaLI sequence. To eliminate nonspecific transcription initiation from the plasmid sequence, the 5-terminus of the noncoding Determination of minimum promoter sequence region (NCR), BamHI-AccII ( Fig. 2A) , was inserted upstream of the CAT, NDP, and PA sequences of pCAT/19, The PstI-ApaLI sequence contains the E2-binding motif (E2-BM) at nt 585-596, 7-bp Rep sequences, AGGpNDPA/CAT, and pPA/CAT, respectively (Fig. 2B-1) . As TGGA, at nt 636-642 and at nt 645-651, and an initiatorthe promoter activities, though these were not abolished completely. These results suggested that nt 572-652, like sequence (INR-like sequence) TACCAA, at nt 683-688 (Fig. 3A) . To more precisely analyze the PE1ˆE4 sewhich contains 7-bp Rep sequences, is required for the transcriptional activity of PE1ˆE4. quence, we prepared deletion mutants (Fig. 3B-1 ) and assayed for promoter activity. As shown in Fig. 3B-2 , deletion of nt 572-622 or nt 572-631 from pPA/CAT and Gel-shift assay deletion of nt 572-631 from pBA/PA/CAT did not impair promoter activities. In contrast, deletions of nt 572-652
Next, we used gel-shift assay to examine protein binding on the 7-bp Rep. As shown in Fig. 4 , a protein from from pPA/CAT and pBA/PA/CAT significantly decreased E1ˆE4 mRNA (Chow et al., 1987) . Thus, it is presumed that PE1ˆE4, which lacks an identifiable TATA element, would be highly active in tumors caused by HPV-11. However, early promoters of HPVs are relatively weak in cultured cells when examined by transient transfection assay. With CAT-expression plasmids, we showed that the sequence from nt 632 to nt 743 (PstIApaLI) has the highest promoter activity and that the upstream sequence from nt 235 to nt 572 (NdeI -PstI) strongly suppressed activity. The construct, pCAT/19, showed relatively high nonspecific transcription initiation from the vector's sequence. The HPV-11 NCR sequence (BamHI -AccII, nt 7072 -7513) has been supposed to contain negative regulatory elements that acts at the level of mRNA stability and a mRNA 3-processing poly(A) signal at nt 7457 -7462. Because the sequence is similar with the negative regulatory elements of HPV-16 late mRNA (Kennedy et al., 1990 (Kennedy et al., , 1991 . Therefore, nonspecific transcription in the plasmid sequence would terminate within the BamHI -AccII sequence. Furthermore, the BamHI -AccII sequence has shown to contain a constitutive enhancer at nt 7224 -7496, when it was assayed for SV40 pro- It has been proposed that transcription factors such as the TFIID complex, which contains TATA-box bindHeLa nuclear extract bound to ds-oligonucleotide coning proteins (TBPs), interact similarly with ''TATA-less'' taining the 7-bp Rep sequence, 5-GATGAGGTGGACand ''TATA-containing'' promoters (Conaway and Con-AAGGTGGA. Addition of either 20-or 200-fold excess of away, 1993). At least two models have been proposed unlabeled oligonucleotide inhibited binding. However, a to explain how TATA-less promoters work. (i) TATA-400-fold excess of another oligonucleotide, 5-ATTCGAless promoters usually contain an initiator (INR) ele-TCGGGGCGGGGCGAGC, which contained Sp1-BM of ment that specifically interacts with the transcription the SV40 early promoter, did not inhibit binding. Moreinitiation complex (Kaufmann and Smale, 1994) . (ii) A over, purified Sp1 (Promega Co. Ltd.) did not bind to the transcription activator, Sp1, can activate most cellular 7-bp Rep (data not shown). These results showed that and viral TATA-less promoters, depending on the the binding protein was not Sp1.
presence of a coactivator (Pugh and Tjian, 1992) . According to these models, it seems likely that, in In vitro transcription and primer extension PE1ˆE4, nt 632 -743 should be sufficient to support To determine the transcription initiation site, an in vitro transcription and that the 7-bp Rep would interact with transcription assay was done using the 439-bp DNA fragone or more cellular proteins that could function as ment from pPA/CAT (Fig. 5A ). As shown in Fig. 5B, when activators. The 7-bp Rep has relatively high homology 50 or 100 ng of template DNA was used, two labeled to AAGAGGAGGA, the Sp1-BM, which is located improducts were detected. The upper and lower bands repmediately upstream of the E2-BM in the E6 promoter of resent RNAs of approximately 430 and 293 bases, re-HPV-11 (Gloss and Bernard, 1990) . However, a cellular spectively. However, the upper band may have been a protein other than Sp1 bound to the 7-bp Rep. These nonspecific product in that the same band was observed results imply that the cellular protein functions as an even when the HeLa nuclear extract was pretreated at activator for PE1ˆE4. A possible INR function for the 42Њ for 15 min before use (data not shown). Primer exten-7-bp Rep cannot be overlooked, however, since resion using an HS21 primer yielded a 120-bp single-strand moval of the 7-bp Rep significantly reduced the activ-DNA (Fig. 5B) . This suggested that one of the transcripity. Furthermore, promoter activity of p632A/CAT, but tion initiation sites on pPA/CAT was near nt 719. not p653A/CAT increased three-to fourfold (data not DISCUSSION shown) upon cotransfection of an adenovirus type 5 E1A-expression plasmid, implying that nt 632 -743 It has been shown that more than 98% of viral RNA in HPV-11-infected condyloma acuminata consists of function as a minimum promoter. In vitro transcription M1: 584, 489, 431, 404, 293, 242, 190 bp; M2: 501/489, 431, 404, 331, 242, 190 and primer extension showed that one of the transcripto ACCGN4CGGT (Hirochika et al., 1988) , could be one of the reasons for weak activation. tion initiation sites is near nt 719. The sequence TAC-CAAA at nt 683 -689, about 30 bp upstream of a preRecently, Grassmann et al. (1996) identified a differentiation-inducible promoter in the E7 ORF of HPV-16 in dicted transcription initiation site, may act as an INR in vivo, because the sequence is similar to that of raft cultures of a cell line containing high copy numbers of episomal HPV-16 DNA and that the transcript initiated the SV40 late promoter, TACCTAA, to which the TFIID protein binds (Wiley et al., 1992) . However, the possifrom the promoter had a coding potential for an E1ˆE4 fusion protein. They have discussed the differentiationbility that the 7-bp Rep acts as an INR and as the transcription start at near nt 674 should be considered, dependent activation of the promoter in relation to a possible binding of C/EBP protein on a GCAAT motif, a varibecause removal of the 7-bp Rep significantly reduced promoter activity.
ant of CCAAT, which locates just 29 bp upstream of the transcription initiation site. In HPV-11, the mechanism by To examine the suppressive effect of the NdeI-PstI sequence (nt 235-572) on the SV40 promoter, we inserted which the NdeI-PstI sequence of HPV11 suppresses the PE1ˆE4 activity is unclear. However, it may be of interest it upstream of or downstream from the SV40 promoter. When the sequence was inserted immediately upstream to study the putative binding of certain proteins, such as Oct-1 and YY-1, that strongly suppress the HPV-18 of the promoter in sense orientation, activity was suppressed by 41.6% (data not shown), suggesting that the promoter (zur Hausen, 1994) or a possible inhibition of the suppression by C/EBP protein binding on GCAAT/ NdeI-PstI sequence may regulate PE1ˆE4 in tumors. However, cotransfection of an HPV-11 E2 expression plas-CCAAT motifs which locate at nt 326-330, nt 379-383, and nt 610-614 of HPV-11 DNA. mid, pRS-E2-11 (Hirochika et al., 1987) , with pNDPA/CAT showed that the E2 protein weakly activated the promoter Frattini et al. (1996) have reported differentiation-dependent and episomal gene-dependent late gene ex-(1.58-fold), but did not overcome the suppressive effect of the NdeI-PstI sequence (not shown in figure) , suggesting pression of HPV-31 with raft cultures, in which amplification of viral DNA and production of viral particles octhat the E2 binding motif ACCN6GGT at nt 585-596 does not have a regulatory function in vivo. The low binding curred. In natural tumor, such as condyloma acuminata, the HPV-11 DNA rapidly replicates as episome and is affinity of E2 to the ACCN6GGT, compared with the binding HPV-11 EARLY PROMOTER, PE1ˆE4 the E2 transactivator and the TATA box binding protein depends on not integrated into the host cell chromosome. This might core promoter structure. EMBO J. 13, [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] be one of the reasons why E1ˆE4 mRNA is expressed Hirochika, H., Broker, T. R., and Chow, L. T. (1987) . Enhancers and so abundantly in natural tumors.
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